Document is current
Any future updates will be listed below
-
Authors
Inzucchi, Silvio E.
Tan, Xi
Liang, Yuanjie
Yedigarova, Larisa
Xie, Lin
de Havenon, Adam
-
Funding
Funding for this research was provided by:
Novo Nordisk, Inc
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 25 November 2024
First Online: 17 December 2024
Declarations
:
: Silvio E. Inzucchi reports honorarium for consulting and/or clinical trial committee work from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Merck, Pfizer, and Bayer. He has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. Xi Tan, Yuanjie Liang, Larisa Yedigarova, and Lin Xie are employed by Novo Nordisk Inc. Adam de Havenon reports NIH/NINDS funding (K23NS105924, R01NS130189, UG3NS130228), has received investigator-initiated clinical research funding from the AAN, has received consultant fees from Integra and Novo Nordisk, has received royalty fees from UpToDate, and has equity in Titin KM and Certus.
: As this study involved retrospectively collected de-identified data, which was analyzed without further interaction with the human subjects, it was deemed to be exempt from institutional review board review.
